Daiichi Sankyo enters into outsourcing agreement to manufacture AstraZeneca COVID-19 Vaccine in Japan


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Daiichi Sankyo enters into outsourcing agreement to manufacture AstraZeneca COVID-19 Vaccine in Japan
Daiichi Sankyo will use undiluted solutions provided by AstraZeneca to manufacture COVID-19 vaccines in Japan

Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) is pleased  to announce that it recently entered into  an  outsourcing agreement with  AstraZeneca  K.K.  (hereinafter,  AstraZeneca)  to manufacture the  AstraZeneca-developed COVID-19  vaccine, AZD1222,  in  Japan.

In  order  to  play  a  part  in  the  COVID-19  vaccine  manufacturing and  supply  scheme  agreed upon  between AstraZeneca  and  the  government  of Japan,  Daiichi  Sankyo will  use  undiluted  solutions  provided  by  AstraZeneca  to  manufacture  COVID-19  vaccines  in  the  country,  including  vial  filling  and  packaging,  in  accordance with the outsourcing agreement.

The  manufacture  of  the COVID-19  vaccine, AZD1222,   will  be  undertaken  by  Daiichi  Sankyo  Biotech  Company, Limited,  a subsidiary of Daiichi Sankyo, at a facility dedicated to the Ministry of Health, Labour and Welfare’s “project to establish a system for developing and producing novel influenza virus vaccines.”

As it strives to help restore safety and security in society through the early eradication of COVID-19, Daiichi Sankyo, in  addition  to  ensuring  the  stable  supply  of  the AstraZeneca COVID-19  vaccine  in  Japan, will continue to work to advance ongoing research and development of a Nafamostat inhalation formulation (DS-2319) as well as an mRNA vaccine (DS-5670)

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centred around rare diseases and immune disorders. 

Tags : #DaiichiSankyo #AstraZenecaVaccine #Japan #JapanCovidVaccineNews #Nafamostat

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026